JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06695845
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- 🇺🇸
USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Washington Cancer Center, Washington, District of Columbia, United States
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, United States
VYxeoS Liposomal Italian Observational Study iN the Real Practice
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT06143839
- Locations
- 🇮🇹
Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Ospedale di Bolzano, Bolzano, Italy
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06113237
- Locations
- 🇺🇸
United Biosource LLC, Morgantown, West Virginia, United States
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT06108050
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸Duke University Medical Center - Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy
- Conditions
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 207
- Registration Number
- NCT05875974
- Locations
- 🇺🇸
Advanced Respiratory and Sleep Medicine, PLLC, Huntersville, North Carolina, United States
🇺🇸CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸Intrepid Research, Cincinnati, Ohio, United States
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 170
- Registration Number
- NCT05869773
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
🇧🇪Private Practice RESPISOM Namur, Namur, Belgium
🇺🇸University of Arizona, Tucson, Arizona, United States
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT05864846
- Locations
- 🇺🇸
University of Pennsylvania - Penn Epilepsy Center, Philadelphia, Pennsylvania, United States
🇺🇸University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸University of Florida Health - Department of Neurology, Gainesville, Florida, United States
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 158
- Registration Number
- NCT05772429
- Locations
- 🇫🇷
GH Est - Hôpital Femme Mère Enfant, Bron, France
🇫🇷CHU Bordeaux - service adulte, Bordeaux, France
🇫🇷CHU Grenoble - service adulte, Grenoble, France